ImmuCell Corporation (ICCC) and Aptevo Therapeutics Inc. (NASDAQ:APVO) Comparing side by side

ImmuCell Corporation (NASDAQ:ICCC) and Aptevo Therapeutics Inc. (NASDAQ:APVO), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmuCell Corporation 11.18M 3.88 1.46M -0.28 0.00
Aptevo Therapeutics Inc. 19.54M 2.03 49.36M -2.21 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of ImmuCell Corporation and Aptevo Therapeutics Inc.

Net Margins Return on Equity Return on Assets
ImmuCell Corporation -13.06% -6.3% -4.4%
Aptevo Therapeutics Inc. -252.61% -78.8% -51.1%

Liquidity

ImmuCell Corporation has a Current Ratio of 3.2 and a Quick Ratio of 2.1. Competitively, Aptevo Therapeutics Inc.’s Current Ratio is 3.9 and has 3.7 Quick Ratio. Aptevo Therapeutics Inc.’s better ability to pay short and long-term obligations than ImmuCell Corporation.

Insider and Institutional Ownership

Institutional investors owned 14.2% of ImmuCell Corporation shares and 32.9% of Aptevo Therapeutics Inc. shares. About 4.2% of ImmuCell Corporation’s share are owned by insiders. On the other hand, insiders owned about 0.6% of Aptevo Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ImmuCell Corporation -0.53% -6.54% 9.22% 5.67% -16.09% -15.13%
Aptevo Therapeutics Inc. -10.87% -40.92% -60.5% -59.88% -45.62% -51.65%

For the past year ImmuCell Corporation has stronger performance than Aptevo Therapeutics Inc.

Summary

On 8 of the 10 factors ImmuCell Corporation beats Aptevo Therapeutics Inc.

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.